Recent Updates
Recently added Catalysts

OD-001

Phase 1

Undisclosed | Small molecule | Other |Odyssey Therapeutics, Inc.|Trials Updated: Oct 28, 2026

OD-001 target and mechanism

ModalitySmall molecule

Also known as [14C]OD-001

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment8

FDA Designations

No designations recorded

OD-001 clinical trials

OD-001 · 1 trial · 1 indication

Phase 1 1
NCT07900607The Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]OD-001 in Healthy Male ParticipantsHealth Volunteers
NOT YET_RECRUITING8 Analytics
PHASE1NOT YET_RECRUITING
The Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]OD-001 in Healthy Male Participants
Health Volunteers
NCT079006078
Unlock trial analytics

Study Endpoints

Primary Endpoints

Mass balance recovery of total radioactivity in all excreta: CumAe
Day 1 to Day 8
Mass balance recovery of total radioactivity in all excreta: Cum%Ae
Day 1 to Day 8
Number of OD-001 metabolites at ≥10% of total exposure of [14C]-radiolabel in blood
Day 1 to Day 8
Identity of OD-001 metabolites at ≥10% of total exposure of [14C]-radiolabel in blood by LC-MS and NMR
Day 1 to Day 8

Secondary Endpoints

Rate of elimination of [14C]OD-001 in excreta by Ae
Day 1 to Day 8
Rate of elimination of [14C]OD-001 in excreta by %Ae
Day 1 to Day 8
Secondary Rate of elimination of [14C]OD-001 in excreta by CumAe
Day 1 to Day 8
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeOTHER

Treatment Arms

ArmTypeDescription
[14C]OD-001EXPERIMENTALoral solution

Interventions

NameTypeDescription
[14C]OD-001DRUG\[14C\]OD-001
Unlock Study Design Details

Eligibility Criteria

Age Range30 Years to 65 Years
SexMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Aged 30 to 65 years inclusive at the time of signing informed consent * Must agree to adhere to the contraception requirements. In addition, vasectomised male participants with partners of childbearing potential must have received medical assessment of the surgical success of ...

Countries:United Kingdom
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWOct 28, 2026NCT07900607NEW_TRIAL: changed
LOWOct 28, 2026NCT07900607NEW_TRIAL: changed

Explore more on BiopharmaWatch

Odyssey Therapeutics, Inc. (ODTX)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with OCompanies A to ZEvery biotech and pharma company we track